Edison issues report on BB Biotech (BION)

  London, UK, 22 January 2025   . BB Biotech (BION) is the largest biotech investor among its investment company peers. The company is focused on achieving long-term capital growth by investing in high-quality biotech assets developing and marketing innovative drugs. The new year has started on a very positive note for BION. Pharmaceutical giant Johnson & Johnson (J&J) recently announced plans to acquire one of BION’s core holdings, Intra-Cellular Therapies, at a 40% premium. Intra-Cellular comprised 6.1% of BB Biotech’s portfolio at end-Q324, although its share will be larger now. Since J&J’s announcement, BB Biotech’s net asset value (NAV) has risen by 3.4% in absolute terms, 3.1 percentage points ahead of its benchmark, the Nasdaq Biotech Index. This note considers the broader implications of this transaction for the biotech sector. Click here to read the full report. All reports published by Edison are available to download free of charge from its website www.edisongroup.com Edison is authorised and regulated by the Financial Conduct Authority. Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities. For more information, please contact Edison: enquiries@edisongroup.com Connect with Edison on:   LinkedIn www.linkedin.com/company/edison-group-/ X  www.x.com/edison_inv_res YouTube www.youtube.com/edisonitv